Integrated Screening and Assay Capabilities Facilitate Peptide Drug Discovery

Peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages, including high specificity, potent activity, and relatively low toxicity. These attributes make peptides highly attractive for targeting complex diseases, including cancer, metabolic disorders, and autoimmune conditions. As the demand for innovative peptide drugs continues to grow, the need for advanced technologies and integrated approaches in early discovery becomes paramount.

In this webinar, experts discuss methodologies in peptide discovery using DNA-encoded library (DEL) technology, phage display, and mRNA display, as well as showcasing our comprehensive bioassay platform and customized approach for peptide ligand validation. This webinar provides an in-depth perspective on strategies crucial for accelerating research focused on peptide therapeutics.